Compare Ginkgo Bioworks Holdings Inc (DNA) vs Iris Energy Limited (IREN) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

IREN stock trades at $35.15, down 9.15% in the last 24 hours, reflecting bearish technical signals despite strong analyst buy ratings. The company reported revenue of $501.02M in 2025 with a net income of $86.94M, but recent quarterly EPS misses and a projected net loss of -$703M for 2026 highlight profitability challenges. Key developments include a $9.7 billion deal with Microsoft and a strategic pivot from Bitcoin mining to AI cloud services, positioning IREN in the high-growth AI infrastructure sector.

The outlook for IREN is mixed: significant upside exists from analyst price targets averaging $81.00, driven by AI demand and contracted revenue, but risks include execution on massive capital expenditure, intense competition, and current negative profitability. Investors face high volatility amid transformative growth ambitions versus near-term financial strain.